Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Cytos sign vaccine agreement

Pfizer and Cytos sign vaccine agreement

15th August 2008

Cytos Biotechnology and Pfizer have signed an agreement to research certain novel vaccines for a number of human diseases.

The research, development, manufacturing and commercialisation deal also includes an option and license agreement for products discovered.

Under the terms of the deal, Pfizer will pay Cytos an initial fee of 10 million Swiss francs (4.9 million pounds), with the company eligible for further milestone payments of up to 140 million Swiss francs.

After the completion of all research programmes and exercising of its options, Pfizer will then acquire the exclusive global rights to commercialise vaccines based on the Immunodrug technology from Cytos incorporating disease targets outside its own programmes.

Cytos Biotechnology will however retain the rights to make and commercialise different disease targets in the same diseases.

Dr Mark Dyer, executive vice-president of business development at Cytos Biotechnology, said: “The vaccine market, including therapeutic vaccines, represents an increasingly attractive segment of the healthcare market.”

He added this partnership agreement establishes Immunodrugs as the vaccine of choice for pharmaceutical companies.

In June 2008, Pfizer entered into a partnership agreement with the University of Pennsylvania School of Medicine to collaborate on clinical care and policy as well as scientific research and clinical development.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.